<DOC>
	<DOC>NCT00620685</DOC>
	<brief_summary>The hypothesis of this study is that the p38 inhibitor (PH-797804) will be safe and well tolerated in subjects with rheumatoid arthritis who are taking methotrexate and will not effect the blood levels of methotrexate.</brief_summary>
	<brief_title>A Study To Evaluate The Safety And Pharmacokinetic Profile Of A P38 Inhibitor (PH-797804) In Subjects With Rheumatoid Arthritis Who Are Also Taking Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Adult with RA for at least 6 months Stable weekly dosage of oral methotrexate 12.5 25 mg/week Severe, progressive and/or uncontrolled other disease Chronic or recent serious infection; current infection Concomitant use of RA therapy other than methotrexate with some exceptions</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Arthritis, rheumatoid</keyword>
</DOC>